RE:RE:RE:RE:RE:Reviews Urology 2015Finally someone else singing my tune. "In patients with papillary-only tumours (**90% of NMIBC patients**), MCNA was even more effective with rates of 35.1% and 32.2% at 1 year and 2 years, respectively." First line therapy - off label should be quickly adopted. I think a CRR to the tune of <50% with no virtually no toxicity (and no hazmat suits needed) will be too compelling for urologists not to use. all we need is the fda greenlight.... with="" no="" virtually="" no="" toxicity="" (and="" no="" hazmat="" suits="" needed)="" will="" be="" too="" compelling="" for="" urologists="" not="" to="" use.="" all="" we="" need="" is="" the="" fda="">